Atezolizumab extends OS for certain patients with non-small cell lung cancer

Sandra Horning, MD
Sandra Horning

Atezolizumab as first-line monotherapy prolonged OS compared with chemotherapy alone for certain patients with non-small cell lung cancer, according to the agent’s manufacturer.

Atezolizumab (Tecentriq, Genentech) is a monoclonal antibody designed to bind with PD-L1.

The randomized phase 3 IMpower110 study included 572 PD-L1-selected, chemotherapy-naive patients with advanced nonsquamous or squamous NSCLC who did not have ALK or EGFR mutations .

Researchers randomly assigned them 1:1 to atezolizumab monotherapy — which continued until loss of clinical benefit as assessed by investigators — or chemotherapy.

Chemotherapy regimens included cisplatin or carboplatin combined with either pemetrexed or gemcitabine, followed by maintenance with pemetrexed for those with nonsquamous disease or best supportive care for those with squamous disease. Chemotherapy continued until disease progression, unacceptable toxicity or death.

The study achieved its primary endpoint, as results of an interim analysis showed atezolizumab significantly extended OS compared with chemotherapy alone for patients with high PD-L1 expression. Complete results will be submitted for presentation at an upcoming medical meeting.

The study will continue to final analysis to determine the potential benefit of atezolizumab for patients with lower levels of PD-L1 expression.

Secondary endpoints included PFS, objective response rate and duration of response.

Healio.com will continue to follow this trial and publish more detailed results when they are released, either through presentation at a scientific meeting or publication in a peer-reviewed journal.

Results of IMpower110 showed a tezolizumab exhibited a safety profile comparable to that observed in prior studies. Researchers identified no new safety signals.

“We are encouraged that Tecentriq monotherapy has shown a significant survival benefit over c hemotherapy as an initial treatment [for] people with squamous or nonsquamous non-small cell lung cancer with high PD-L1 expression,” Sandra Horning, MD, chief medical officer and head of global product development at Genentech, said in a company-issued press release. “These findings reinforce the potential of Tecentriq to play an important role in the treatment of multiple forms of lung cancer, and we look forward to discussing these data with health authorities.”

Sandra Horning, MD
Sandra Horning

Atezolizumab as first-line monotherapy prolonged OS compared with chemotherapy alone for certain patients with non-small cell lung cancer, according to the agent’s manufacturer.

Atezolizumab (Tecentriq, Genentech) is a monoclonal antibody designed to bind with PD-L1.

The randomized phase 3 IMpower110 study included 572 PD-L1-selected, chemotherapy-naive patients with advanced nonsquamous or squamous NSCLC who did not have ALK or EGFR mutations .

Researchers randomly assigned them 1:1 to atezolizumab monotherapy — which continued until loss of clinical benefit as assessed by investigators — or chemotherapy.

Chemotherapy regimens included cisplatin or carboplatin combined with either pemetrexed or gemcitabine, followed by maintenance with pemetrexed for those with nonsquamous disease or best supportive care for those with squamous disease. Chemotherapy continued until disease progression, unacceptable toxicity or death.

The study achieved its primary endpoint, as results of an interim analysis showed atezolizumab significantly extended OS compared with chemotherapy alone for patients with high PD-L1 expression. Complete results will be submitted for presentation at an upcoming medical meeting.

The study will continue to final analysis to determine the potential benefit of atezolizumab for patients with lower levels of PD-L1 expression.

Secondary endpoints included PFS, objective response rate and duration of response.

Healio.com will continue to follow this trial and publish more detailed results when they are released, either through presentation at a scientific meeting or publication in a peer-reviewed journal.

Results of IMpower110 showed a tezolizumab exhibited a safety profile comparable to that observed in prior studies. Researchers identified no new safety signals.

“We are encouraged that Tecentriq monotherapy has shown a significant survival benefit over c hemotherapy as an initial treatment [for] people with squamous or nonsquamous non-small cell lung cancer with high PD-L1 expression,” Sandra Horning, MD, chief medical officer and head of global product development at Genentech, said in a company-issued press release. “These findings reinforce the potential of Tecentriq to play an important role in the treatment of multiple forms of lung cancer, and we look forward to discussing these data with health authorities.”

    See more from Immuno-Oncology Resource Center